Denmark
Ousia Pharma is a Danish biotech firm that focuses on developing peptide-small molecule drugs to address obesity. The company, established in 2022, is a spin-out from the University of Copenhagen and concentrates on creating novel peptide-drug conjugates for treating obesity and metabolic diseases. Ousia Pharma's unique approach involves utilizing peptides to deliver modulators of synaptic plasticity, aimed at achieving potent and sustained weight loss without compromising safety. The main aim of the company is to progress the development of their lead weight loss drug candidate (OP-56) within the general obesity space.
Notably, Ousia Pharma's latest investment, a Convertible Note investment, took place on 16 March 2023. The investment came from BioInnovation Institute Venture House, signifying their confidence in the potential of Ousia Pharma's innovative approach to addressing obesity through peptide-small molecule drugs.
Ousia Pharma operates in the Biotechnology and Pharmaceutical industries, with its headquarters located in Denmark. With their strong focus on addressing the global issue of obesity, Ousia Pharma is positioned to make a significant impact in the field of metabolic diseases with their pioneering approach. The recent investment speaks to the growing interest and support from venture capitalists in the promising future of Ousia Pharma's novel drug development efforts.
